Latest News
STAT+: Supreme Court lets Trump slash NIH research funds
And other biotech updates from The Readout.
STAT+: He was 21 when he programmed MyChart. Now he’s the president of Epic
He was 21 when he programmed MyChart — now he’s the president of Epic. STAT sat down with Sumit Rana for a wide-ranging interview.
STAT+: FDA says it will publish reports of adverse events tied to drugs on daily basis
The FDA said it has begun publishing reports of adverse events concerning drugs on a daily basis, instead of quarterly, as it has in the past.
CDC advisory panel member no longer trusts CDC
Good morning. We've got a meaty issue for you today. In particular, I urge you to spend some time with Jason Mast's story. It's another heartbreaking...
STAT+: FDA agrees to speed review for an ultra-rare disease drug
The FDA has agreed to speed up a review of a rare disease drug developed by Stealth BioTherapeutics, a notable step after the company said it may have...
STAT+: Pharmalittle: We’re reading about Gilead’s HIV drug, FDA speeding review of a rare disease drug, and more
CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness
STAT+: FDA decision on Replimune has ripple effects
And more biotech news updates from The Readout.
STAT+: Gilead’s Kite Pharma acquires Interius BioTherapeutics for $350 million
Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.
STAT+: CDC boosts security in new strategy
This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.
STAT+: FDA approves Ionis drug that prevents swelling attacks caused by a rare disease
Ionis Pharmaceuticals won FDA approval for a drug that prevents painful swelling attacks triggered by a rare genetic condition, hereditary angioedema.
STAT+: Supreme Court lets Trump slash NIH research funds
STAT+: He was 21 when he programmed MyChart. Now he’s the president of Epic
STAT+: FDA says it will publish reports of adverse events tied to drugs on daily basis
CDC advisory panel member no longer trusts CDC
STAT+: FDA agrees to speed review for an ultra-rare disease drug
STAT+: Pharmalittle: We’re reading about Gilead’s HIV drug, FDA speeding review of a rare disease drug, and more
STAT+: FDA decision on Replimune has ripple effects
STAT+: Gilead’s Kite Pharma acquires Interius BioTherapeutics for $350 million
STAT+: CDC boosts security in new strategy
STAT+: FDA approves Ionis drug that prevents swelling attacks caused by a rare disease
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago